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Reverse transcription-tropic murine leukemia virus (N-MLV) but not B-tropic MLV (B-MLV) infection.
Here we study B30.2/SPRY domain mutants of human TRIM5α that acquire the ability to inhibit B-MLV
infection prior to reverse transcription without losing the ability to restrict N-MLV infection. Remarkably,
these mutants gain the ability to decrease the amount of particulate B-MLV capsids in the cytosol of infected
cells. In addition, these mutants gain the ability to restrict SIVmac and HIV-2 infection. B-MLV and SIVmac
infections were blocked by the mutant TRIM5α proteins prior to reverse transcription. Thus, the range of
retroviruses restricted by human TRIM5α can be increased by changes in the B30.2/SPRY domain, which also
result in the ability to cause premature uncoating of the restricted retroviral capsid.
© 2008 Elsevier Inc. All rights reserved.Introduction
Following entry into cells, some retroviruses encounter dominant
blocks to infection that act prior to reverse transcription (Cowan et al.,
2002;Munk et al., 2002). For example, human immunodeﬁciency virus
(HIV-1) is blocked in the cells ofmost OldWorldmonkeys. Infection by
the simian immunodeﬁciency virus of macaques (SIVmac) encounters
similar restrictions in New World monkeys (Hofmann et al., 1999).
These restrictions are mediated by TRIM5α, a tripartite motif protein
with a RING, B-box 2 and coiled-coil (CC) domain, as well as a carboxy-
terminal B30.2/SPRY domain (Stremlau et al., 2004). The TRIM5α
B30.2/SPRY domain is essential for retroviral restriction, and differ-
ences in the antiretroviral potency of TRIM5α from different species
map to this domain (Ohkura et al., 2006; Perron et al., 2006; Sawyer
et al., 2005; Song et al., 2005a; Stremlau et al., 2005; Yap et al., 2005).
Human TRIM5α (TRIM5αhu) potently restricts N-tropic murine
leukemia virus (N-MLV) but not B-MLV infection (Hatziioannou et al.,
2004; Keckesova et al., 2004; Perron et al., 2004). TRIM5αhu partially
inhibits equine infectious anemia virus (EIAV) and feline immunodeﬁ-e, 44 Binney Street – JFB 824,
. Sodroski).
l rights reserved.ciency virus (FIV) infections (Diaz-Griffero et al., 2007a,b). TRIM5αhu does
notefﬁciently restrictHIV-1 infection;however, a single aminoacid change
in its B30.2/SPRY domain (TRIM5αhu R332P) converts TRIM5αhu into a
potent restrictor of HIV-1 and SIVmac infections (Li et al., 2006; Stremlau et
al., 2005; Yap et al., 2005). In contrast to the wild-type protein, TRIM5αhu
R332P efﬁciently binds HIV-1 capsid–nucleocapsid (CA–NC) complexes
assembled in vitro (Li et al., 2006). Thus, variation in the surface of the
B30.2/SPRY domain can modulate the speciﬁcity of retroviral restriction.
Changes in arginine 110 of the N-MLV capsid (CA) protein
determine susceptibility to TRIM5αhu-mediated restriction. Changing
this arginine residue to a glutamic acid residue, the corresponding
amino acid from B-MLV, generates a virus that can partially overcome
TRIM5αhu restriction (Perron et al., 2004; Towers et al., 2000).
Conversely, replacement of glutamic acid 110 of the B-MLV capsidwith
an arginine residue generates a virus that is susceptible to TRIM5αhu
restriction. Particulate N-MLV capsids in the cytoplasm of TRIM5αhu-
expressing cells undergo a premature conversion to soluble capsid
proteins (Perron et al., 2007). Decreases in the amounts of particulate
cytosolic capsids have been observed for other retroviruses, including
HIV-1, in cells expressing a restricting TRIM5α protein (Diaz-Griffero
et al., 2007a,b; Stremlau et al., 2006). Thus, there is a good correlation
between the restriction of a retrovirus and the premature uncoating of
the viral capsid in the cytoplasm of the infected cell. However, other
Fig. 1. Expression, localization andMLV-restricting ability of TRIM5αhu Y336A and Y336K. (A)Wild-type, Y336A and Y336K TRIM5αhu proteins were stably expressed in canine Cf2Th
cells. Cell lysates were Western blotted and probed with antibodies directed against the HA epitope tag (top panel) or β-actin (bottom panel). (B) Cf2Th cells transduced with the
empty LPCX vector or stably expressing the wild-type and mutant TRIM5αhu proteins were ﬁxed and stained using a ﬂuorescein isothiocyanate-conjugated anti-HA antibody, as
described in Materials and methods. Representative confocal microscope images are shown. (C–G) Cf2Th cells transduced with the empty LPCX vector or expressing the indicated
wild-type or mutant TRIM5αhu proteins were challenged with B-MLV-GFP (C), N-MLV-GFP (D), Mo-MLV-GFP (E), NBNN-GFP (F) and BNBB-GFP (G). GFP-positive cells were counted.
Similar results were obtained in three independent experiments.
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Fig. 2. Levels of MLV reverse transcripts in infected cells expressing TRIM5αhu Y336A
and Y336K. Cf2Th cells expressing the indicated wild-type and mutant TRIM5αhu
proteins or containing the empty vector LPCX were challenged at an MOI of 0.2 with
DNAse-pretreated B-MLV-GFP (A) or N-MLV-GFP (B). After 7 h, cells were lysed and total
DNA extracted. The levels of viral DNA were measured by quantitative real-time PCR,
using a probe against GFP as described in Materials and methods. Similar results were
obtained in three independent experiments.
235F. Diaz-Griffero et al. / Virology 378 (2008) 233–242mechanistic models for TRIM5α-mediated restriction, including those
that involve blocks after reverse transcription, have been proposed
(Anderson et al., 2006; Wu et al., 2006).
In this report, we study changes in the B30.2/SPRY domain of
TRIM5αhu that result in an increase in the ability to restrict B-MLV
infection prior to reverse transcription. Remarkably, these mutants
gain the ability to decrease the amount of cytosolic particulate B-MLV
capsid during infection. These mutants also acquire the ability to
restrict SIVmac potently by interfering with a step in the virus life cycle
prior to reverse transcription.
Results
TRIM5αhu B30.2/SPRY domain mutants that gain the ability to inhibit
B-MLV infection
Changes in tyrosine 336 of TRIM5αhu have been reported to allow
this protein to inhibit B-MLV as well as N-MLV infection (Maillard
et al., 2007). We took advantage of this gain of function to investigate
the mechanism of B-MLV restriction by these mutants. We stably
expressed the wild-type TRIM5αhu protein and two mutants,
TRIM5αhu Y336A and Y336K, in canine Cf2Th cells. These cells were
used to assess the level of expression and localization of the TRIM5αhu
variants; viral restriction, viral cDNA formation and the fate of
retroviral capsids following virus entry into the cell were evaluated.
Thewild-type, Y336A and Y336K TRIM5αhu proteins were expressed
at similar steady-state levels in the Cf2Th cells (Fig. 1A). Wild-type and
mutant TRIM5αhu proteins localized in the cytoplasm, concentrating in
speckles (Fig. 1B). As previously reported (Maillard et al., 2007), both
TRIM5αhu Y336A and Y336K gain the ability to restrict B-MLV potently
(Fig.1C) without losing the ability to restrict N-MLV (Fig.1D). In addition,
TRIM5αhu Y336K can partially block the infection of the NB-tropic
Moloney MLV (Mo-MLV) (Fig. 1E). Replacing arginine at position 110 in
theN-MLVcapsidwithglutamic acid, the corresponding residue fromthe
B-MLV capsid, rendered this virus (NBNN) partially resistant towild-type
TRIM5αhu; however, theNBNNvirus remained sensitive to theTRIM5αhu
Y336A and Y336K mutants (Fig. 1F). The converse capsid mutant, BNBB,
which is identical to the B-MLV capsid except for an arginine residue at
position 110, was restricted by the wild-type and mutant TRIM5αhu
proteins (Fig. 1G). Thus, the TRIM5αhu Y336A and Y336K mutants can
potently restrict both N-MLV and B-MLV; in contrast, the wild-type
TRIM5αhu protein restricts only N-MLV or amodiﬁed form of B-MLV that
has an arginine residue at position 110 of the capsid protein.
Restriction of B-MLV infection prior to the completion of reverse
transcription by TRIM5αhu Y336A and Y336K
The above results indicate that TRIM5αhu Y336A and Y336K
potently restrict B-MLV infection. To investigate themechanism of this
gain of virus-restricting ability, we measured the synthesis of late
reverse transcripts (LRTs) during B-MLV infection of cells expressing
the wild-type and mutant TRIM5αhu proteins. Compared with the
levels of LRTs in control LPCX cells or in cells expressing wild-type
TRIM5αhu, the levels of LRTs in cells expressing TRIM5αhu Y336A and
Y336K were signiﬁcantly lower (Fig. 2A). When these cells were
incubated with N-MLV, the levels of LRTs were lower in cells
expressing the wild-type and mutant TRIM5αhu proteins, compared
with those in the control LPCX cells (Fig. 2B). We conclude that the
TRIM5αhu Y336A and Y336K mutants block B-MLV and N-MLV
infection prior to the completion of reverse transcription.
Effects of TRIM5αhu Y336A and Y336K on the fate of cytosolic MLV capsids
To investigate further the mechanism underlying the ability of the
TRIM5αhu tyrosine 336 mutants to block B-MLV infection, we
examined the effect of expression of wild-type and mutant TRIM5αhuproteins on the state of the viral capsid in the cytosol of infected cells.
As previously demonstrated (Perron et al., 2007), the amount of
particulate N-MLV capsid in the cytosol of cells expressing the wild-
type TRIM5αhu protein was signiﬁcantly reduced compared with that
seen in the control LPCX-transduced cells (Fig. 3A). The relative
increase in soluble N-MLV capsid protein indicates that the particulate
N-MLV capsid was converted into soluble forms in the TRIM5αhu-
expressing cells. This premature uncoating of the N-MLV capsid was
also seen in cells expressing the TRIM5αhu Y336A and Y336K mutants
(Fig. 3A).
The effect of expression of the TRIM5αhu Y336A and Y336K
proteins on the state of the cytosolic B-MLV capsid was examined.
Remarkably, both mutants caused a decrease in the amount of
cytosolic B-MLV capsid, relative to the levels observed in cells
transduced with the empty LPCX vector or expressing the wild-type
TRIM5αhu protein (Figs. 3B and C). Thus, concomitant with a gain of B-
MLV-restricting ability, the TRIM5αhu tyrosine 336 mutants acquired
the ability to decrease the amount of particulate B-MLV capsid in the
cytosol of infected cells.
Effects of proteasome inhibition on viral cDNA and cytosolic capsids
We tested the ability of TRIM5αhu and TRIM5αhu Y336A to de-
crease the amount of particulate capsid in the presence of MG115, a
proteasomal inhibitor, during infection with N-MLV and B-MLV,
respectively (Figs. 3D and E). Proteasome inhibition resulted in a
general increase in the amount of pelletable N-MLV and B-MLV
capsids in the cytosol of infected cells, regardless of the expression of a
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Fig. 4. Inhibition of SIVmac and HIV-2 infection in cells expressing TRIM5αhu Y336A and
Y336K. (A) Cf2Th cells expressing the indicated wild-type and mutant TRIM5αhu
proteins or containing the empty vector LPCX were challenged with SIVmac-GFP. GFP-
positive cells were counted. (B) Cf2Th cells transduced with the empty LPCX vector or
stably expressing wild-type and mutant TRIM5αhu proteins were challenged with
SIVmac-GFP at an MOI of 0.4. After 7 h, cells were lysed and total DNA extracted. The
levels of viral DNA were measured by quantitative real-time PCR, using a probe against
GFP as described in Materials and methods. Similar results were obtained in three
independent experiments. (C) Cf2Th cells expressing the indicated wild-type and
mutant TRIM5αhu proteins or containing the empty vector LPCX were challenged with
HIV-2-GFP. GFP-positive cells were counted. Similar results were obtained in two
independent experiments.
237F. Diaz-Griffero et al. / Virology 378 (2008) 233–242restricting TRIM5α protein in the cells. This increase in the back-
ground level of particulate capsid obscured any effect of TRIM5αhu
Y336A on B-MLV capsids (Fig. 3E); however, the TRIM5αhu-induced
uncoating of N-MLV capsids, which are more efﬁciently recovered
from sucrose gradients (Perron et al., 2007), was still evident after
treatment with the proteasome inhibitor (Fig. 3D).
We next examined the effects of proteasome inhibition on the
levels of late reverse transcripts (LRTs) in control Cf2Th cells or Cf2Th
cells expressing TRIM5αhu or TRIM5αhu Y336A, following exposure to
N-MLV or B-MLV. The cells were treated with the proteasome
inhibitor, MG115, or with the control solvent, DMSO. As was seen for
the levels of cytosolic particulate capsids above, proteasome inhibition
resulted in a general increase in the levels of LRTs, even in cells not
expressing TRIM5αhu variants (Fig. 3F). Relative to the level of N-MLV
LRTs in the control cells, LRT levels in the TRIM5αhu-expressing cells
were reduced in both DMSO-treated and MG115-treated cells. The
reduction in the level of B-MLV LRTs due to expression of TRIM5αhu
Y336Awas observed in the Cf2Th cells treated with the DMSO solvent,
but not in the MG115-treated cells. Thus, the levels of LRTs (Fig. 3F)
closely paralleled the levels of cytosolic particulate N-MLV and B-MLV
capsids (Figs. 3D and E).
The effects of proteasome inhibition on the efﬁciency of N-MLV
and B-MLV infection of control Cf2Th cells or Cf2Th cells expressing
TRIM5αhu or TRIM5αhu Y336Awere examined. Slight increases in the
percentages of N-MLV- and B-MLV-infected cells were observed
following proteasome inhibition (Fig. 3F), as has been previously
observed for HIV-1 infection (Stremlau et al., 2006; Wu et al., 2006;
Schwartz et al., 1998; Fredericksen et al., 2002; Dueck and Guatelli,
2007). However, TRIM5αhu and TRIM5αhu Y336A efﬁciently inhibited
infection by N-MLV and B-MLV, respectively, of cells treated with the
MG115 proteasome inhibitor. Thus, proteasome inhibition resulted in
general increases in the levels of particulate cytosolic capsids and
LRTs, but minimally affected the efﬁciency of MLV infection and
restriction by TRIM5αhu.
TRIM5αhu Y336A and Y336K potently restrict SIVmac and HIV-2 infection
The wild-type TRIM5αhu protein does not restrict infection by
SIVmac (Song et al., 2005b). However, TRIM5αhu Y336A and Y336K
potently restricted SIVmac infection (Fig. 4A). The Y336K mutant was
more potent in this regard than the Y336A variant (Fig. 4A). As shown
in Fig. 4B, the expression of TRIM5αhu Y336A and Y336K resulted in a
marked decrease in the synthesis of LRTs following infection. Thus,
changes in tyrosine 336 allow TRIM5αhu to restrict infection of SIVmac
prior to reverse transcription.
The wild-type TRIM5αhu protein partially restricts infection by
HIV-2 (Ylinen et al., 2005). The potency of HIV-2 restriction by
TRIM5αhu was increased by the Y336A and Y336K changes (Fig. 4C).
Effect of TRIM5αhu Y336A and Y336K on other retroviruses
To test if infection by other retroviruses can be restricted by the
TRIM5αhu Y336A and Y336K proteins, we challenged Cf2Th cells
expressing these mutants with different retroviruses, including HIV-1,
SIVagm, FIV, EIAV and BIV (Figs. 5A–E). As expected, expression of the
wild-type TRIM5αhu protein resulted in modest inhibition of HIV-1,
EIAV and FIV infections (Figs. 5A–C). The Y336A and Y336K mutants
were slightly more effective than the wild-type TRIM5αhu protein inFig. 3. Fate of the cytosolic MLV capsid and levels of late reverse transcripts following infecti
mutant TRIM5αhu proteins, or transducedwith the empty LPCX control vector, were incubate
cells were preincubated with 10 μMMG115, a proteasomal inhibitor, or the control DMSO solv
was continued for another 4 h. Following lysis of the target cells, cytoplasmic lysates were an
and particulate (“Pellet”) fractions, as described in Materials and methods. The fractions w
protein. (F) Cf2Th cells were preincubated for 1 hwith DMSO or 10 μMMG115 and then expos
preserved for assessment of the percentage of GFP-positive cells at 48 h after infection. The
quantitative real-time PCR, utilizing a probe against GFP.restricting HIV-1 and EIAV infection (Figs. 5A and B). By contrast, the
Y336K, but not the Y336A, mutant exhibited diminished ability to
restrict FIV infection, compared with the wild-type TRIM5αhu protein
(Fig. 5C). The wild-type and mutant TRIM5αhu proteins did not affect
SIVagm or BIV infection (Figs. 5D and E). Thus, changes in tyrosine 336
in the B30.2/SPRY domain selectively increase or decrease the ability
of TRIM5αhu to restrict infection by various retroviruses.on of cells expressing TRIM5αhu Y336A and Y336K. Cf2Th cells expressing wild-type or
dwith VSVG-pseudotyped N-MLV (A, D) or B-MLV (B, C, E) VLPs for 4 h. In D and E, target
ent for 1 h at 37 °C. N-MLV and B-MLV VLPs were then added and the incubation at 37 °C
alyzed directly (“Total”) or were separated on sucrose gradients into endosomal, soluble
ere analyzed by Western blot, using an antibody directed against the MLV p30 capsid
ed to VSVG-pseudotyped N-MLV-GFP or B-MLV-GFP. After 4 h, an aliquot of the cells was
remaining cells were lysed and cytoplasmic lysates were used for DNA extraction and
Fig. 6. Effect of the R332P change on the anti-retroviral activity of TRIM5αhu Y336K.
Cf2Th cells expressing the indicated TRIM5α protein or the empty LPCX vector were
challenged with HIV-1-GFP (A), B-MLV-GFP (B), N-MLV-GFP (C), and SIVmac-GFP (D).
GFP-positive cells were counted. Similar results were obtained in three independent
experiments.
Fig. 5. Inhibition of other retroviruses by TRIM5αhu Y336A and Y336K. Cf2Th cells
expressing the indicated wild-type and mutant TRIM5αhu proteins or the empty LPCX
vector were challenged with HIV-1-GFP (A), EIAV-GFP (B), FIV-GFP (C), SIVagm-GFP (D)
and BIV-GFP (E). GFP-positive cells were counted. Similar results were obtained in three
independent experiments.
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increased its anti-HIV-1 activity
The R332P mutant of TRIM5αhu potently blocks HIV-1 and SIVmac
infection (Li et al., 2006; Yap et al., 2005). To determine if the R332P
change would enhance the antiretroviral potency of TRIM5αhu Y336K,
we constructed TRIM5αhu R332P/Y336K. The TRIM5αhu R332P/Y336K
protein restricted HIV-1 infection slightly more efﬁciently than
TRIM5αhu Y336K (Fig. 6A). By contrast, the addition of the R332P
change slightly decreased the restriction activity of TRIM5αhu Y336K
against B-MLV, N-MLV and SIVmac (Figs. 6B–D). Thus, inmost cases, the
phenotypes of the TRIM5αhu R332P and Y336K changes are not
additive.
239F. Diaz-Griffero et al. / Virology 378 (2008) 233–242Ability of additional TRIM5αhu tyrosine 336 variants to restrict different
retroviruses
The retrovirus-restricting abilities of additional TRIM5αhu mutants
altered in tyrosine 336 were examined. TRIM5αhu Y336F has the more
conservative substitution of a phenylalanine for tyrosine 336. TRIM5αhu
Y336Δ has tyrosine 336 deleted. Themutantswere efﬁciently expressed
in Mus dunni tail ﬁbroblasts cells (Fig. 7A) and tested for the ability toFig. 7. Expression and retrovirus-restricting ability of TRIM5αhu variants with other changes
stably expressed inMus dunni tail ﬁbroblasts. Cell lysates were Western blotted and probed
(B) Mus dunni tail ﬁbroblasts transduced with the empty LPCX vector or stably expressing
indicated amounts of recombinant GFP-expressing viruses. GFP-positive cells were countedinhibit infectionby recombinantN-MLV, B-MLV,HIV-1,HIV-2andSIVmac
expressing GFP (Fig. 7B). A B-MLVmutant with two amino acid changes
in the capsid protein, B-MLV N82D L117H, was also tested for
susceptibility to restriction by these TRIM5αhu variants. None of the
tyrosine 336 changes affected the ability of TRIM5αhu to inhibit N-MLV
infectionpotently. TRIM5αhu Y336K, Y336A and Y336Δ inhibited B-MLV
and HIV-2 infection, but TRIM5αhu Y336F did not. Likewise, TRIM5αhu
Y336F did not inhibit SIVmac infection, and TRIM5αhuY336Δ exhibitedin tyrosine 336. (A) Wild-type (wt) TRIM5αhu or the indicated TRIM5αhu variants were
with antibodies directed against the HA epitope tag (top panel) or actin (bottom panel).
TRIM5αrh or the wild-type and mutant TRIM5αhu proteins were challenged with the
. Similar results were obtained in three independent experiments.
240 F. Diaz-Griffero et al. / Virology 378 (2008) 233–242onlymild inhibition of SIVmac infection. Infection by B-MLV N82D L117H
was not affected by any of the TRIM5αhu variants tested. HIV-1 infection
was only mildly inhibited by TRIM5αhu Y336K and not the other
TRIM5αhu variants with changes in tyrosine 336. Thus, TRIM5αhu and
TRIM5αhu Y336F exhibited similar abilities to restrict infection by
various retroviruses, whereas the TRIM5αhu Y336Δ protein exhibited
restriction activity closer to that of the TRIM5αhu Y336A mutant.
Discussion
The results presented herein underscore previous observations
that alteration of the TRIM5α B30.2/SPRY v1 variable region can
dramatically alter the range of retroviruses restricted (Li et al., 2006;
Maillard et al., 2007; Sawyer et al., 2005; Yap et al., 2005). Some
alterations of tyrosine 336 in TRIM5αhu allow a broadening of the
range of retroviruses potently restricted to include B-MLV, SIVmac and
HIV-2, in addition to N-MLV. This result is reminiscent of the effects of
changes in the nearby residue, arginine 332, in human TRIM5α;
alteration or removal of this arginine creates a protein that acquires
more potent restricting activity against HIV-1 and SIVmac (Yap et al.,
2005; Stremlau et al., 2005; Li et al., 2006). In the case of HIV-1, this
increased restricting ability results from improved binding of the
TRIM5αhu derivative to viral capsid complexes (Li et al., 2006). Given
the proximity of arginine 332 and tyrosine 336, the changes in the
latter residue studied herein likely improve TRIM5αhu binding to the
B-MLV capsid.
Most of the phenotypes observed for the TRIM5αhu Y336A and
Y336K mutants were similar, despite the different nature of the
substituted residues. As was seen for arginine 332 (Li et al., 2006; Yap
et al., 2005), deletion of tyrosine 336 results in a gain of ability to
restrict some retroviruses. The TRIM5αhu mutant lacking tyrosine 336
was similar in phenotype to TRIM5αhu Y336A. By contrast, TRIM5αhu
Y336F exhibited restriction phenotypes similar to those of wild-type
TRIM5αhu. Apparently, an aromatic residue at position 336 of
TRIM5αhu is an impediment to the restriction of some retroviruses
(Maillard et al., 2007).
Remarkably, the gain in restricting activity against B-MLV that
results from the tyrosine 336 changes also results in the acquisition of
two other activities: 1) the ability to inhibit the synthesis of viral
cDNA; and 2) the ability to promote the disappearance of particulate
capsids from the cytosol. These observations support a growing
correlation between TRIM5-mediated restriction of infection and
premature conversion of particulate capsids to soluble proteins (Diaz-
Griffero et al., 2007a,b; Perron et al., 2007; Stremlau et al., 2006). The
results imply a likely mechanistic relationship among these processes,
and support a model in which premature uncoating of the incoming
retroviral capsid by a restricting TRIM5α protein leads to the
disruption of the reverse transcription process.
Inhibition of the proteasome does not relieve TRIM5α-mediated
restriction of retrovirus infection (Stremlau et al., 2006; Anderson
et al., 2006; Wu et al., 2006), but increases the level of viral reverse
transcripts in the target cell (Anderson et al., 2006; Wu et al., 2006).
MLV-infected cells treated with proteasome inhibitors exhibited large
increases in the amount of particulate, cytosolic capsids, regardless of
the expression of TRIM5α in the target cells. Similar increases were
previously observed in the levels of particulate capsids in the cytosol
of HIV-1-infected control cells and cells expressing TRIM5α or
TRIMCyp as a consequence of proteasome inhibition (Diaz-Griffero
et al., 2007a). The levels of late reverse transcripts changed in parallel
with the levels of particulate cytosolic capsids, consistent with the
notion that loss of capsid integrity leads to disruption of reverse
transcription. In many cases, the generalized increases in the levels of
cytosolic capsids and late reverse transcripts resulting from protea-
some inhibition obscured the TRIM5α- or TRIMCyp-mediated
decrease in these parameters (Diaz-Griffero et all, 2007a,b). However,
the efﬁciency with which N-MLV capsids can be recovered fromsucrose gradients allowed detection of human TRIM5α-associated
decreases in pelletable capsid and late reverse transcripts even in the
presence of a proteasome inhibitor. Therefore, an active proteasome is
not absolutely required for the accelerated uncoating of N-MLV
capsids by human TRIM5α, or for its subsequent impact on the
efﬁciency of reverse transcription.
Future studies should further clarify the structural requirements
for TRIM5α interaction with the retroviral capsid and the mechanistic
consequences of this recognition event.
Materials and methods
Creation of cells stably expressing TRIM5α variants
Retroviral vectors encoding wild-type or mutant TRIM5αhu
proteins were created using the pLPCX vector. Recombinant viruses
were produced in 293T cells by cotransfecting the pLPCX plasmids
with the pVPack-GP and pVPack-VSV-G packaging plasmids (Strata-
gene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis
virus (VSV) G envelope glycoprotein, which allows efﬁcient entry into
a wide range of vertebrate cells. Cf2Th canine thymocytes or Mus
dunni tail ﬁbroblasts were transduced and selected in 1–5 μg/ml
puromycin (Sigma).
Infection with viruses expressing green ﬂuorescent protein (GFP)
Recombinant HIV-1, simian immunodeﬁciency viruses from maca-
ques and African green monkeys (SIVmac and SIVagm, respectively), N-
tropic murine leukemia virus (N-MLV) and B-tropic murine leukemia
virus (B-MLV) expressingGFPwere prepared as described (Diaz-Griffero
et al., 2006; Stremlau et al., 2004). The feline immunodeﬁciency virus
(FIV) vector expressing GFP was obtained from System Biosciences
(Mountain View, CA) and was prepared following the manufacturer's
instructions. The equine infectious anemia virus (EIAV) vector expres-
sing GFP was a gift from Dr. John Olsen (Olsen, 1998). Bovine
immunodeﬁciency virus (BIV) vectors expressing GFP were prepared
as described (Berkowitz et al., 2001). All recombinant viruses were
pseudotyped with the VSV G glycoprotein. For infections, 3×104 Cf2Th
cells seeded in 24-well plates were incubated with virus for 24 h. Cells
were washed and returned to culture for 48 h, and then subjected to
FACS analysis with a FACScan (Becton Dickinson). HIV-1, N-MLV, B-MLV,
FIV, BIV, SIVmac, SIVagm and EIAV viral stocks were titrated by serial
dilution on Cf2Th cells to determine the concentration of infectious
viruses. Similarly, viruses used in the experiments shown in Fig. 7 were
titrated inMus dunni tail ﬁbroblasts.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipitation
assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl; 1% sodium
deoxycholate; 0.1% sodium dodecyl sulfate [SDS]; 1% NP-40; 2 mg/ml
aprotinin; 2 mg/ml leupeptin; 1 mg/ml pepstatin A; 100 mg/ml
phenylmethylsulfonyl ﬂuoride). The cell lysates were analyzed by
SDS-PAGE (10% acrylamide), followed by blotting onto nitrocellulose
membranes (Amersham Pharmacia Biotech). Detection of protein by
Western blotting utilized monoclonal antibodies directed against the
HA epitope tags (Roche) andmonoclonal antibodies to β-actin (Sigma)
or actin (Chemicon). Detection of proteins was performed by
enhanced chemiluminescence (NEN Life Sciences Products), using
anti-mouse immunoglobulin (for actin) and anti-rat immunoglobulin
(for HA) secondary antibodies (Amersham Pharmacia Biotech).
Localization of wild-type and mutant TRIM5α proteins
The localization of TRIM5αhu and variants was investigated as
previously described (Diaz-Griffero et al., 2002). Brieﬂy, cells were
241F. Diaz-Griffero et al. / Virology 378 (2008) 233–242grown overnight on 12-mm-diameter coverslips and ﬁxed in 3.9%
paraformaldehyde (Sigma) in phosphate-buffered saline (PBS; Cellgro)
for 30 min. Cells were washed in PBS, incubated in 0.1 M glycine
(Sigma) for 10 min, washed in PBS, and permeabilized with 0.05%
saponin (Sigma) for 30 min. Samples were blocked with 10% donkey
serum (Dako, Carpinteria, CA) for 30 min, and incubated for 1 h with
antibodies. The anti-HA FITC-conjugated 3F10 antibody (Roche) was
used to stain HA-tagged proteins. Subsequently, samples were
mounted for ﬂuorescence microscopy by using the ProLong Antifade
Kit (Molecular Probes, Eugene, OR). Images were obtained with a
BioRad Radiance 2000 laser scanning confocal microscope with Nikon
60× N.A.1.4 optics.
Fate-of-capsid assay
Recombinant N-MLV and B-MLV virus-like particles (VLPs) were
produced by calcium phosphate cotransfection of 293T cells with the
pCIG-N or pCIG-B vectors (Bock et al., 2000), respectively, along with
pVPack-VSV-G at a weight ratio of 15:4, respectively. Stably trans-
duced Cf2Th (1.5×106) cells expressing the different TRIM5αhu
variants were seeded in 80 cm2 ﬂasks. The following day, the cells
were incubated with 5–10 ml (approximately 2.5-5.0×105 reverse
transcriptase units) of N-MLV or B-MLV VLPs at 4 °C for 30 min to
allow viral attachment to the cells. The cells were then shifted to 37 °C
until they were harvested at 4 h post-infection. Cells were washed
three times using ice-cold PBS and detached by treatment with 1.0 ml
of pronase (7.0mg/ml in DMEM) for 5min at 25 °C. The cells were then
washed three times with PBS. The cells were resuspended in 2.5 ml
hypotonic lysis buffer (10mMTris–HCl, pH 8.0,10mMKCl,1mMEDTA
and one complete protease inhibitor tablet) and incubated on ice for
15 min. The cells were lysed using 15 strokes in a 7.0 ml Dounce
homogenizer with pestle B. Cellular debris was cleared by centrifuga-
tion for 3 min at 3000 rpm. To allow assessment of the total input
(Total or Input) MLV p30 capsid protein, 100 μl of the cleared lysate
was collected, made 1× in SDS sample buffer, and analyzed by SDS-
PAGE and Western blotting. Then 2.0 ml of the cleared lysate was
layered onto a 50% sucrose (weight:volume) cushion in 1× PBS and
centrifuged at 125,000 × g for 2 h at 4 °C in a Beckman SW41 rotor.
Following centrifugation, 100 μl of the top-most portion of the
supernatant was collected and made 1× in SDS sample buffer; this
sample is referred to as the soluble p30 fraction. The pellet was
resuspended in 50 μl 1× SDS sample buffer and is referred to as the
particulate p30 fraction. All samples were then subjected to SDS-PAGE
and Western blotting. The MLV p30 protein was detected using a rat
monoclonal antibody puriﬁed from the R187 hybridoma cell line
(American Type Culture Collection).
To examine the effects of proteasome inhibition, the Cf2Th target
cells were incubated in the presence of 10 μM MG115, a proteasome
inhibitor, for 1 h at 37 °C prior to the addition of N-MLV or B-MLV VLPs.
In some experiments, this 1-hour preincubation was not performed,
with no effect on the outcome (data not shown). Following the
preincubation step, viruses and either DMSO or MG115 were
incubated with the target cells at 37 °C for 4 h. Cells were washed,
harvested and processed for the fate-of-capsid assay (see above) or for
measurement of LRTs (see below).
Quantitative real-time PCR
Cf2Th cells expressing wild-type and mutant TRIM5αhu proteins
were challenged at a multiplicity of infection (MOI) of 0.2 for N-MLV-
GFP and B-MLV-GFP, or 0.4 for SIVmac-GFP. Viruses were pretreated
with DNAse to prevent contamination from carry-over plasmid DNA.
As a control to establish background, viruses were heat-inactivated
(30 min at 65 °C). In some cases, the Cf2Th cells were treated with
MG115 (10 μg/ml) or DMSO, as described above. After 4 or 7 h of
incubation with the virus (and compound, if included), cells werelysed and DNA was extracted using a Qiagen Blood Tissue DNA
extraction kit. PCR reactions were prepared using the QuantiTect probe
PCR kit. Each sample contained 100 ng of total cellular DNA. PCR was
carried out using two primers that amplify a 263-bp fragment of GFP:
GFP-fwd: 5′-GAC GTA AAC GGC CAC AAG-3′
GFP-rev: 5′-GGT CTT GTA GTT GCC GTC GT-3′
GFP-Probe: 5′-56-FAM-CCT ACG GCA AGC TGA CCC TGA-36-
TAMRA-3′
The calibration curvewas prepared using anMLV-GFP plasmid. The
background observed for the heat-inactivated viruses was subtracted
from all values.
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